<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107531">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01818063</url>
  </required_header>
  <id_info>
    <org_study_id>12G.376</org_study_id>
    <secondary_id>2012-47</secondary_id>
    <nct_id>NCT01818063</nct_id>
  </id_info>
  <brief_title>Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer</brief_title>
  <official_title>An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Susan G. Komen Breast Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well carboplatin and combination chemotherapy
      with or without veliparib works in treating patients with stage IIB-IIIC breast cancer.
      Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin hydrochloride, and
      cyclophosphamide, work in different ways to stop the growth of tumor cells, either by
      killing the cells or by stopping them from dividing. Veliparib may stop the growth of tumor
      cells by blocking some of the enzymes needed for cell growth. It is not yet known whether
      giving carboplatin and combination chemotherapy are more effective with or without veliparib
      is more effective in treating breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      1) To compare the pathologic complete response (path CR) in patients with stage IIB or stage
      III triple negative breast cancer treated with neoadjuvant paclitaxel and carboplatin to the
      path CR of patients treated with paclitaxel, carboplatin, and veliparib.

      SECONDARY OBJECTIVES:

        1. Relapse free survival (follow-up period of 36 months).

        2. Overall clinical response to neoadjuvant therapy.

        3. To determine whether expression of 5 biomarkers (cytokeratin [CK]5, endothelial growth
           factor receptor [EGFR], excision repair cross complementing 1 [ERCC1], Ki67,
           poly[adenosine diphosphate (ADP)-ribosyl]transferase [Parp1]) correlate with a higher
           pCR in response to a particular treatment combination. 4) To determine whether tumors
           with biomarker signatures that are most like breast cancer (BRCA)-mutated tumors (high
           expression of CK5 and high expression of EGFR), will correlate with a higher likelihood
           of pCR with treatment with a PARP inhibitor in combination with chemotherapy.

      5) To determine whether tumors with high expression of the markers ERCC1, Ki67, and Parp1
      will correlate with a higher rate of pCR with platinum agents in combination with paclitaxel
      or a PARP inhibitor.

      6) To correlate response of tumor on imaging (magnetic resonance imaging [MRI], ultrasound
      [US], and positron emission tomography [PET]/computed tomography [CT]) with path CR.

      7) To correlate levels of circulating tumor cells (CTCs) with pathologic CR.

      TERTIARY OBJECTIVES:

        1. To evaluate additional exploratory biomarkers based on evidence of possible prognostic
           or predictive value: BRCA1/BRCA2 complete mutational and rearrangement test. CK14,
           CK17, cyclin B1, cluster of differentiation (CD)44, CD24, cyclin D1, vimentin,
           thymidine phosphorylase, inhibitor of differentiation (ID)4, p53, p63, p73,
           differentiated embryo-chondrocyte expressed gene (Dec)1, phospho-HistoneH3, thymidylate
           synthase, p16, gammaH2AX, geminin, RAD51.

        2. To determine which arms are best tolerated by patients with co-morbid conditions, such
           as hypertension and diabetes.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive paclitaxel intravenously (IV) and carboplatin IV on day 1 (course 1
      only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence
      of disease progression or unacceptable toxicity. Beginning 21 days after the last course,
      patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment
      repeats every 21 days for 4 courses in the absence of disease progression or unacceptable
      toxicity.

      ARM II: Patients receive veliparib orally (PO) twice daily (BID) on days 1-5. Patients also
      receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12).
      Treatment repeats every 7 days for 12 courses in the absence of disease progression or
      unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin
      hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4
      courses in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 36 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pathologic complete response (PCR)</measure>
    <time_frame>At the time of surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>PCR is defined as the absence of any residual invasive cancer on hematoxylin and eosin (H&amp;E) evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes. The posterior distribution of the odds ratio will be used to assess whether carboplatin and/or carboplatin +veliparib in combination with paclitaxel has a higher PCR compared to each other and simulations will be used to compare to paclitaxel alone. A 95% credible region will be calculated for the odds ratio comparing the two combination treatments, the odds ratio comparing each treatment to paclitaxel alone, the PCR for each treatment regimen, for the difference in the PCR between each combination regimen, and the difference of each combination regimen to paclitaxel alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall clinical response</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of subjects with each category of overall clinical response will be summarized by presence of baseline measureable disease (i.e., complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD], unable to evaluate [UE], neurogenerative disease [ND]). Beta will be used as priors for combination regimens in calculating the posterior distribution of the PCR for each respective treatment group. Among subjects with measurable disease, a 95% credible region will be calculated for the odds ratio for each treatment combination relative to each other.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analyzed using Kaplan-Meier methods, stratified by study group, and the log rank test will be completed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Estrogen Receptor-negative Breast Cancer</condition>
  <condition>HER2-negative Breast Cancer</condition>
  <condition>Progesterone Receptor-negative Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <condition>Triple-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1 (paclitaxel, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (veliparib, paclitaxel, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (paclitaxel, carboplatin)</arm_group_label>
    <arm_group_label>Arm 2 (veliparib, paclitaxel, carboplatin)</arm_group_label>
    <other_name>Taxol</other_name>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (paclitaxel, carboplatin)</arm_group_label>
    <arm_group_label>Arm 2 (veliparib, paclitaxel, carboplatin)</arm_group_label>
    <other_name>cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin-AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (paclitaxel, carboplatin)</arm_group_label>
    <arm_group_label>Arm 2 (veliparib, paclitaxel, carboplatin)</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>Rubex</other_name>
    <other_name>Doxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm 1 (paclitaxel, carboplatin)</arm_group_label>
    <arm_group_label>Arm 2 (veliparib, paclitaxel, carboplatin)</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>cytophosphane</other_name>
    <other_name>Lyophilizedcytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veliparib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm 2 (veliparib, paclitaxel, carboplatin)</arm_group_label>
    <other_name>ABT-888</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent must be obtained prior to any study-related procedures.

          2. Histologically confirmed adenocarcinoma of the breast with the following markers:
             Estrogen receptor negative (&lt;1%), progesterone receptor negative (&lt;1%), and Her-2/neu
             negative (Her-2/neu 0-1+ IHC or FISH ratio &lt;1.8 or average HER2 gene copy number of
             &lt;four signal/nucleus for test systems without internal control probe).

          3. Female ≥ 18 years old.

          4. Clinical stage IIA (T2N0), IIB (T2N1, T3N0) or stage IIIA (T1N2, T2N2, T3N1, T3N2),
             IIIB, or IIIC breast cancer with no prior treatment.

          5. Complete radiology or tumor assessment within 28 days prior to enrollment

               1. Breast MRI

               2. Unilateral Breast Ultrasound

               3. Distant metastatic work-up completed with PET/CT.

               4. If enlarged axillary lymph nodes are found during staging scans, FNA must be
                  performed to determine whether the node is involved with cancer.

               5. If axillary lymph nodes are clinically negative during initial work-up, sentinel
                  node biopsy will be performed prior to initiation of chemotherapy.

          6. ECOG Performance Status of 0 or 1

          7. Adequate organ and hematologic function as evidenced by the following laboratory
             studies within 4 weeks of study enrollment:

               1. Cardiac Ejection Fraction &gt;/= lower limit of normal as determined by 2-D echo or
                  MUGA scan according to institutional standards.

               2. Hematologic function, as follows: Absolute neutrophil count ≥ 1.5 x 109/L,
                  Platelet count ≥ 100 x 109/L and ≤ 850 x 109/L, Hemoglobin ≥ 9 g/dL, PTT and INR
                  &lt; 1.5 x ULN.

               3. Renal function, as follows: Serum creatinine &lt;/= 1.4 mg/dL).

               4. Hepatic function, as follows:Aspartate aminotransferase (AST) ≤ 2.5 x ULN,
                  Alanine aminotransferase (ALT) ≤ 2.5 x ULN , Total bilirubin ≤ 2 x ULN (except
                  for patients with UGT1A1 promoter polymorphism, i.e. Gilbert syndrome, confirmed
                  by genotyping or Invader UGT1A1 molecular assay prior to study enrollment.
                  Patients enrolled with Gilbert syndrome must have total bilirubin &lt; 3 ULN).

          8. Patient must be willing and able to undergo MRI as outlined in protocol.

        Exclusion Criteria:

          1. Known hypersensitivity to doxorubicin, cyclophosphamide, paclitaxel, cremophor or
             medications containing cremophor(miconazole, docetaxel, sandimmune, nelfinavir
             mesylate, propofol, diazepam injection, vitamin K injection, ixabepilone, aci-jel) or
             carboplatin.

          2. Known HIV or active Hepatitis B or C infection.

          3. Prior treatment for the currently diagnosed breast cancer.

          4. Prior treatment with doxorubicin up to 400 mg/m2.

          5. Pre-existing Grade 3 or 4 sensory neuropathy.

          6. History of bleeding diathesis or extensive bleeding requiring blood transfusion
             within 14 days of enrollment.

          7. Major surgical procedure within 4 weeks (28 days) prior to enrollment (port placement
             is not considered a major surgical procedure).

          8. Clinically significant cardiac disease within 12 months of study enrollment,
             including myocardial infarction, unstable angina, congestive heart failure, or
             ongoing arrhythmias requiring medication or pacemaker.

          9. Non-healing wound, ulcer or fracture.

         10. Ongoing or active infection.

         11. Pregnant (i.e., positive beta-human chorionic gonadotropin test) or lactating

         12. Not willing to use a highly effective method of birth control (i.e. those which
             result in low failure rates, less than 1% per year), defined as intrauterine devices,
             barrier methods (condoms, contraceptive sponges, diaphragms, vaginal rings used with
             spermicidal jellies or creams), oral contraceptive pills, or sexual abstinence.
             Contraception must be used during the study.

         13. T0 tumors

         14. Active dental infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiffany Avery, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiffany Avery, MD, MPH</last_name>
    <phone>215-955-1661</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Research Management Office</last_name>
    <phone>215-955-1661</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorraine Tafra, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lorraine Tafra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Craig Shriber, MD</last_name>
    </contact>
    <investigator>
      <last_name>Craig Shriber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Avery, MD, MPH</last_name>
      <phone>215-955-1661</phone>
    </contact>
    <contact_backup>
      <last_name>Clinical Research Management Office</last_name>
      <phone>215-955-1661</phone>
    </contact_backup>
    <investigator>
      <last_name>Tiffany Avery, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronald Cantor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederick Fellin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edith Mitchell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lewis Rose, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Ramirez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allison Zibelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Chapman, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Avnish Bhatia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Jaslow, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Atrayee Basu Mallick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam Berger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Brus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Rosenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Palazzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Cristofanilli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Lazar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodore Tsangaris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shannon Pulhalla, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shannon Pulhalla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org</url>
    <description>Thomas Jefferson University Hospitals</description>
  </link>
  <reference>
    <citation>Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2011;16 Suppl 1:61-70. doi: 10.1634/theoncologist.2011-S1-61. PubMed PMID: 21278442.</citation>
    <PMID>21278442</PMID>
  </reference>
  <reference>
    <citation>Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34.</citation>
    <PMID>17671126</PMID>
  </reference>
  <reference>
    <citation>Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007 May 1;109(9):1721-8.</citation>
    <PMID>17387718</PMID>
  </reference>
  <reference>
    <citation>Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, Green VL, Brawley OW, Oprea-Ilies GM, Gabram SG. High prevalence of triple-negative tumors in an urban cancer center. Cancer. 2008 Aug 1;113(3):608-15. doi: 10.1002/cncr.23569.</citation>
    <PMID>18484596</PMID>
  </reference>
  <reference>
    <citation>Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 2010 May;36(3):206-15. doi: 10.1016/j.ctrv.2009.12.002. Epub 2010 Jan 8. Review.</citation>
    <PMID>20060649</PMID>
  </reference>
  <reference>
    <citation>NCCN. NCCN Clinical Practice Guidelines in Oncology, Version 2.2011. 2011.</citation>
  </reference>
  <reference>
    <citation>Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15;21(6):976-83.</citation>
    <PMID>12637460</PMID>
  </reference>
  <reference>
    <citation>Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005 Jun 1;23(16):3686-96. Epub 2005 May 16.</citation>
    <PMID>15897552</PMID>
  </reference>
  <reference>
    <citation>Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008 Apr 17;358(16):1663-71.</citation>
    <PMID>18420499</PMID>
  </reference>
  <reference>
    <citation>Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1275-81. Epub 2008 Feb 4.</citation>
    <PMID>18250347</PMID>
  </reference>
  <reference>
    <citation>Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15;11(16):5678-85.</citation>
    <PMID>16115903</PMID>
  </reference>
  <reference>
    <citation>Wang S, Yang H, Tong F, Zhang J, Yang D, Liu H, Cao Y, Liu P, Zhou P, Cheng L, Liu M, Guo J. Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. Gan To Kagaku Ryoho. 2009 Feb;36(2):255-8.</citation>
    <PMID>19223741</PMID>
  </reference>
  <reference>
    <citation>Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007 Apr 15;13(8):2329-34.</citation>
    <PMID>17438091</PMID>
  </reference>
  <reference>
    <citation>Perez EA, Moreno-Aspitia A, Aubrey Thompson E, Andorfer CA. Adjuvant therapy of triple negative breast cancer. Breast Cancer Res Treat. 2010 Apr;120(2):285-91. doi: 10.1007/s10549-010-0736-z. Epub 2010 Jan 22. Review.</citation>
    <PMID>20094772</PMID>
  </reference>
  <reference>
    <citation>Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008 Nov;19(11):1847-52. doi: 10.1093/annonc/mdn395. Epub 2008 Jun 20.</citation>
    <PMID>18567607</PMID>
  </reference>
  <reference>
    <citation>Frasci G, Comella P, Rinaldo M, Iodice G, Di Bonito M, D'Aiuto M, Petrillo A, Lastoria S, Siani C, Comella G, D'Aiuto G. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol. 2009 Jul;20(7):1185-92. Epub 2009 Feb 13.</citation>
    <PMID>19218307</PMID>
  </reference>
  <reference>
    <citation>Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA. Poly(ADP-Ribose) polymerase inhibition: &quot;targeted&quot; therapy for triple-negative breast cancer. Clin Cancer Res. 2010 Oct 1;16(19):4702-10. doi: 10.1158/1078-0432.CCR-10-0939. Epub 2010 Sep 21. Review.</citation>
    <PMID>20858840</PMID>
  </reference>
  <reference>
    <citation>Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 Jul 9;361(2):123-34. Epub 2009 Jun 24.</citation>
    <PMID>19553641</PMID>
  </reference>
  <reference>
    <citation>O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011 Jan 20;364(3):205-14. Epub 2011 Jan 5.</citation>
    <PMID>21208101</PMID>
  </reference>
  <reference>
    <citation>Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, Surber BW, Ready DB, Soni NB, Ladror US, Xu AJ, Iyer R, Harlan JE, Solomon LR, Donawho CK, Penning TD, Johnson EF, Shoemaker AR. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012 Jan 15;18(2):510-23. doi: 10.1158/1078-0432.CCR-11-1973. Epub 2011 Nov 29.</citation>
    <PMID>22128301</PMID>
  </reference>
  <reference>
    <citation>Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62. doi: 10.1158/1078-0432.CCR-11-2890. Epub 2012 Jan 30.</citation>
    <PMID>22291137</PMID>
  </reference>
  <reference>
    <citation>Comen EA, Robson M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J. 2010 Jan-Feb;16(1):48-52. doi: 10.1097/PPO.0b013e3181cf01eb. Review.</citation>
    <PMID>20164690</PMID>
  </reference>
  <reference>
    <citation>Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol. 2010 May;21(5):961-7. doi: 10.1093/annonc/mdq041. Epub 2010 Mar 8.</citation>
    <PMID>20211870</PMID>
  </reference>
  <reference>
    <citation>Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol. 2002 May 15;20(10):2495-9.</citation>
    <PMID>12011127</PMID>
  </reference>
  <reference>
    <citation>Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006 Jan;5(1):27-36. Review.</citation>
    <PMID>16485344</PMID>
  </reference>
  <reference>
    <citation>Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 Jul;86(1):97-100. Epub 2009 May 13.</citation>
    <PMID>19440188</PMID>
  </reference>
  <reference>
    <citation>Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics. 2005 Mar;61(1):92-105.</citation>
    <PMID>15737082</PMID>
  </reference>
  <reference>
    <citation>Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 2005 Jun;61(2):540-5.</citation>
    <PMID>16011702</PMID>
  </reference>
  <reference>
    <citation>Chen JQ, Russo J. ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta. 2009 Dec;1796(2):162-75. doi: 10.1016/j.bbcan.2009.06.003. Epub 2009 Jun 13. Review.</citation>
    <PMID>19527773</PMID>
  </reference>
  <reference>
    <citation>Hergueta-Redondo M, Palacios J, Cano A, Moreno-Bueno G. &quot;New&quot; molecular taxonomy in breast cancer. Clin Transl Oncol. 2008 Dec;10(12):777-85. Review.</citation>
    <PMID>19068448</PMID>
  </reference>
  <reference>
    <citation>Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008 May 20;26(15):2568-81. doi: 10.1200/JCO.2007.13.1748. Review.</citation>
    <PMID>18487574</PMID>
  </reference>
  <reference>
    <citation>Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res. 2009 Apr 15;69(8):3625-33. doi: 10.1158/0008-5472.CAN-08-3426. Epub 2009 Mar 31.</citation>
    <PMID>19336573</PMID>
  </reference>
  <reference>
    <citation>Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF; Breast Cancer Linkage Consortium. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005 Jul 15;11(14):5175-80.</citation>
    <PMID>16033833</PMID>
  </reference>
  <reference>
    <citation>Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009 Nov 25;139(5):871-90. Review.</citation>
    <PMID>19945376</PMID>
  </reference>
  <reference>
    <citation>Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011 Jul;121(7):2750-67. doi: 10.1172/JCI45014.</citation>
    <PMID>21633166</PMID>
  </reference>
  <reference>
    <citation>Ruckhäberle E, Karn T, Engels K, Turley H, Hanker L, Müller V, Schmidt M, Ahr A, Gaetje R, Holtrich U, Kaufmann M, Rody A. Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data. Eur J Cancer. 2010 Feb;46(3):549-57. doi: 10.1016/j.ejca.2009.11.020. Epub 2009 Dec 18.</citation>
    <PMID>20022486</PMID>
  </reference>
  <reference>
    <citation>Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Dopazo J, Rivas C, Benítez J. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat. 2005 Mar;90(1):5-14.</citation>
    <PMID>15770521</PMID>
  </reference>
  <reference>
    <citation>Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010 Jun;134(6):907-22. doi: 10.1043/1543-2165-134.6.907. Erratum in: Arch Pathol Lab Med. 2010 Aug;134(8):1101.</citation>
    <PMID>20524868</PMID>
  </reference>
  <reference>
    <citation>Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, Persons DL, Tubbs RR, Hammond ME; College of American Pathologists. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 2009 Apr;133(4):611-2. doi: 10.1043/1543-2165-133.4.611.</citation>
    <PMID>19391661</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
